- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04849117
Effect of Bilateral Transversus Thoracis Muscle Plane Block in Patients Undergoing Coronary Artery Bypass Graft Surgery. (PARACABS)
Effect of Bilateral Transversus Thoracis Muscle Plane Block on Postoperative Morphine Consumption in Patients Undergoing Elective On-pump Coronary Artery Bypass Graft Surgery: a Retrospective Study.
Coronary artery bypass graft surgery is the standard surgical treatment for coronary disease. However, there is no consensus on analgesic management in patients undergoing CABG.
The aim of the study is to evualuate efficacy of bilateral transversus thoracis muscle plane (TTMP) block combined with systemic analgesia, compared to systemic analgesia only, in patients undergoing elective on-pump CABG surgery.
Our main hypothesis is that a bilateral TTMP block performed after CABG surgery could reduce morphine consumption during the first 48 hours.
The investigators conducted an age, gender and type of surgery-matched retrospective cohort study in the Montpellier University Hospital (France).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Montpellier, Francia, 34295
- Uh Montpellier
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
"TTMP Block" group : fifty consecutive patients who underwent elective on-pump coronary artery bypass graft ± valve surgery after October 2019, with a postoperative analgesic protocol including a bilateral TTMP block, associate with systemic analgesia.
"Systemic Analgesia" group : age, gender and type of surgery-matched patients who underwent elective on-pump coronary artery bypass graft ± valve surgery before September 2019, with a postoperative analgesic protocol based on systemic analgesia only.
Descripción
Inclusion criteria:
- To be over 18
- To be scheduled for CABG surgery in the center of the study during the study period.
Exclusion criteria:
- Chronic pain or opioid use before surgery
- Recent thoracic regional analgesia (< 1 month)
- Preoperative dementia or other neurologic or psychiatric disease incompatible with VAS pain scoring.
- Other technique of regional anesthesia (e.g. thoracic epidural)
- Opposition to data collection
Secondary exlusion criteria:
- Postoperative prolonged sedation in ICU (> 12 hours)
- Postoperative surgical complication requiring surgical revision during the first two days.
- Opposition to data collection expressed secondarily
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Retrospectivo
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Systemic analgesia
Patients received only systemic analgesia : Acetaminophen, Ketoprofen, and Nefopam were administered systematically.
Morphine was administered if necessary, according to our institutional pain management protocol.
|
|
|
Bilateral TTMP block + systemic analgesia
Patients received the same protocol of systemic analgesia associated with a bilateral TTMP block performed during the first four hours after ICU admission, before tracheal tube removal.
|
In the "TTMP block" group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal.
Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected "single-shot" in the tranversus thoracis muscle plane.
The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
cumulative morphine consumption
Periodo de tiempo: postoperative day 2
|
cumulative morphine consumption during the first two days.
cumulative morphine consumption on postoperative day 0, 1 and 2, including the morphine administered in intensive care unit, and on postoperative day 1 and 2.
|
postoperative day 2
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative pain assessed
Periodo de tiempo: postoperative day 0, 1 and 2
|
Postoperative pain assessed by visual analog scale (VAS) scoring
|
postoperative day 0, 1 and 2
|
|
Postoperative nausea and vomiting
Periodo de tiempo: hospital day 7
|
Postoperative nausea and vomiting
|
hospital day 7
|
|
Occurrence of prurit
Periodo de tiempo: postoperative day 7
|
Occurrence of prurit
|
postoperative day 7
|
|
rate of Delirium
Periodo de tiempo: postoperative day 7
|
rate of Delirium
|
postoperative day 7
|
|
rate of Constipation
Periodo de tiempo: postoperative day 7
|
rate of Constipation
|
postoperative day 7
|
|
rate of Urinary retention
Periodo de tiempo: until postoperative day 7
|
rate of Urinary retention
|
until postoperative day 7
|
|
rate of Hypotension
Periodo de tiempo: until postoperative day 7
|
rate of Hypotension
|
until postoperative day 7
|
|
Pleural drain duration
Periodo de tiempo: day 20
|
Pleural drain duration
|
day 20
|
|
Urinary catheter duration
Periodo de tiempo: day 20
|
Urinary catheter duration
|
day 20
|
|
Duration of hospitalization in ICU
Periodo de tiempo: day 20
|
Duration of hospitalization in ICU
|
day 20
|
|
In-hospital length of stay
Periodo de tiempo: day 20
|
In-hospital length of stay
|
day 20
|
|
Occurrence of atrial fibrillation
Periodo de tiempo: until postoperative day 7
|
Occurrence of atrial fibrillation
|
until postoperative day 7
|
|
rate of Pneumonia
Periodo de tiempo: until postoperative day 7
|
rate of Pneumonia
|
until postoperative day 7
|
|
acute kidney injury
Periodo de tiempo: until postoperative day 7
|
acute kidney injury
|
until postoperative day 7
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Pierre Sentenac, MD, PhD, Uh Montpellier
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- RECHMPL19_0582
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .